Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-HF)
Sponsor: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
This PHASE1/PHASE2 trial investigates Heart Failure and is currently actively recruiting participants. Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
Status: Unknown → Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 5 earlier versions
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2022 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Repairon GmbH
- University Medical Center Freiburg
- University Medical Center Goettingen
For direct contact, visit the study record on ClinicalTrials.gov .